Fibroblast growth factor receptor 3D receptor: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 11: | Line 11: | ||
**[[1fgk]], [[3kxx]], [[3ky2]], [[4rwi]], [[5flf]] – hFGFR1 TKD (mutant) - human <br /> | **[[1fgk]], [[3kxx]], [[3ky2]], [[4rwi]], [[5flf]] – hFGFR1 TKD (mutant) - human <br /> | ||
**[[4wun]], [[5am6]], [[5ew8]], [[5o49]], [[5o4a]], [[6mzw]], [[6c1o]], [[6mzq]], [[6mzw]] – hFGFR1 TKD + inhibitor <br /> | **[[4wun]], [[5am6]], [[5ew8]], [[5o49]], [[5o4a]], [[6mzw]], [[6c1o]], [[6mzq]], [[6mzw]] – hFGFR1 TKD + inhibitor <br /> | ||
**[[1agw]], [[1fgi]], [[2fgi]], [[3c4f]], [[3js2]], [[3rhx]], [[4f63]], [[4f64]], [[4f65]], [[3tt0]], [[4nk9]], [[4nka]], [[4nks]], [[5b7v]], [[5am7]], [[4rwj]], [[4rwk]], [[4rwl]], [[4uwb]], [[4uwc]], [[4zsa]], [[5uq0]], [[5vnd]], [[5ur1]], [[6c18]], [[6c19]], [[6c1b]], [[6c1c]], [[5z0s]], [[6agx]], [[6itj]], [[6nvl]], [[6p68]], [[6p69]] – hFGFR1 TKD (mutant) + inhibitor <br /> | **[[1agw]], [[1fgi]], [[2fgi]], [[3c4f]], [[3js2]], [[3rhx]], [[4f63]], [[4f64]], [[4f65]], [[3tt0]], [[4nk9]], [[4nka]], [[4nks]], [[5b7v]], [[5am7]], [[4rwj]], [[4rwk]], [[4rwl]], [[4uwb]], [[4uwc]], [[4zsa]], [[5uq0]], [[5vnd]], [[5ur1]], [[6c18]], [[6c19]], [[6c1b]], [[6c1c]], [[5z0s]], [[6agx]], [[6itj]], [[6nvl]], [[6p68]], [[6p69]], [[7ozb]], [[7ozd]], [[7ozf]], [[7ozy]], [[7wcw]] – hFGFR1 TKD (mutant) + inhibitor <br /> | ||
**[[5zv2]] – hFGFR1 TKD (mutant) + anti-cancer drug<br /> | **[[5zv2]], [[7wcl]] – hFGFR1 TKD (mutant) + anti-cancer drug<br /> | ||
**[[3krj]] – hFGFR1 TKD residues 538-678, 753-922 (mutant) + inhibitor <br /> | **[[3krj]] – hFGFR1 TKD residues 538-678, 753-922 (mutant) + inhibitor <br /> | ||
**[[1xr0]] – hFGFR1 residues 409-430 + FGFR signaling adaptor N terminal - NMR<br /> | **[[1xr0]] – hFGFR1 residues 409-430 + FGFR signaling adaptor N terminal - NMR<br /> | ||
| Line 46: | Line 46: | ||
**[[3cly]], [[6v6q]] – hFGFR2 TKD (mutant) with PTR + ACP <br /> | **[[3cly]], [[6v6q]] – hFGFR2 TKD (mutant) with PTR + ACP <br /> | ||
**[[5eg3]] – hFGFR2 TKD (mutant) with PTR + ACP + phospholipase C γ<br /> | **[[5eg3]] – hFGFR2 TKD (mutant) with PTR + ACP + phospholipase C γ<br /> | ||
**[[3ri1]], [[6lvk]], [[6lvl]] – hFGFR2 TKD + inhibitor<br /> | **[[3ri1]], [[6lvk]], [[6lvl]], [[8e1x]] – hFGFR2 TKD + inhibitor<br /> | ||
**[[7kia]], [[7kie]] – hFGFR2 TKD (mutant) + inhibitor<br /> | **[[7kia]], [[7kie]] – hFGFR2 TKD (mutant) + inhibitor<br /> | ||
| Line 86: | Line 86: | ||
**[[4tye]], [[4tyg]], [[4tyi]], [[4tyj]] – hFGFR4 TKD <br /> | **[[4tye]], [[4tyg]], [[4tyi]], [[4tyj]] – hFGFR4 TKD <br /> | ||
**[[4qqj]], [[4qqt]] – hFGFR4 TKD (mutant) <br /> | **[[4qqj]], [[4qqt]] – hFGFR4 TKD (mutant) <br /> | ||
**[[5jkg]], [[5nwz]], [[5nud]], [6nvg]], [[6nvh]], [[6nvi]], [[6nvj]], [[6nvk]], [[6v9c]], [[7dtz]] – hFGFR4 TKD + inhibitor<br /> | **[[5jkg]], [[5nwz]], [[5nud]], [6nvg]], [[6nvh]], [[6nvi]], [[6nvj]], [[6nvk]], [[6v9c]], [[7dtz]], [[7f3m]], [[7v29]], [[7vjl]], [[7wct]], [[7ybo]], [[7yc1]], [[7yc3]] – hFGFR4 TKD + inhibitor<br /> | ||
**[[6yi8]] – hFGFR4 TKD + drug<br /> | **[[6yi8]] – hFGFR4 TKD + drug<br /> | ||
**[[6jpj]], [[5xff]], [[5xfj]], [[6iuo]], [[6iup]], [[6jpe]], [[6jpj]] – hFGFR4 TKD (mutant) + inhibitor<br /> | **[[6jpj]], [[5xff]], [[5xfj]], [[6iuo]], [[6iup]], [[6jpe]], [[6jpj]], [[7wcx]], [[7ybp]], [[7ybx]] – hFGFR4 TKD (mutant) + inhibitor<br /> | ||
**[[4qrc]], [[4r6v]], [[4qqc]], [[4qq5]], [[4uxq]], [[4xcu]] – hFGFR4 TKD (mutant) + irreversible inhibitor<br /> | **[[4qrc]], [[4r6v]], [[4qqc]], [[4qq5]], [[4uxq]], [[4xcu]] – hFGFR4 TKD (mutant) + irreversible inhibitor<br /> | ||
**[[6j6y]] – hFGFR4 LBD D2 + antibody<br /> | **[[6j6y]] – hFGFR4 LBD D2 + antibody<br /> | ||
**[[7n1j]], [[7tyd]] – hFGFR4 LBD D3 + binder<br /> | |||
}} | }} | ||
[[Category:Topic Page]] | [[Category:Topic Page]] | ||